PTO/SB/06b (08-03)
Approved for use through 06/30/2006, OHB 0651-0031
U.S. Patient and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

fuse as many shoots as noo Sheet 1 of 1

| Complete if Known | |
|------------------------|---------------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Nemed Inventor | Bart DE CORTE |
| Group Art Unit | 1624 |
| Examiner Name | VENKATARAMAN BALASUBRAMANIAN |
| Attorney Docket Number | JAB 1425 |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | (| |
|------------------------|--------------|--|--|----|
| Examiner's nitials* | Cite No.' | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | Translation | Τ² |
| M | | VINGERHOETS, Antiviral activity TMC 125 SDM, CROI, San Francisco, Feb. 2004 | No | |
| | | ARNOLD, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003 | No . | |
| | | VINGERHOETS, Resistance before/after therepy - TMC 125C207, XII Resistance Mexico, June 2003 | No | |
| 1 | | VINGERHOETS, Resistance profile clinical isolates TMC 125, XII Resistance Mexico, June 2003 | No . | |
| • | | GAZZARD, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002 | No | |
| | | LANGE, TMC 125 decay rate vs ERA, CROI Seattle, Feb, 2002 | No | 1 |
| | | GAZZARD, 7 day treatment-experienced, WAC Barcelona, Jul. 2002 | No | |
| | | LEWI, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003 | No | 1. |
| | | M-P de BETHUNE. TMC 125 resistance profiles, Resistance, Mexico, June 2003 | No | 1 |
| | | VINGERHOETS, TMC 125-C207 resistance analysis, Resistance, Mexico, June 2003 | No | |
| | | TMC 125 for 7 days in HIV-1+ Individuals with NNRTI resistance (TMC 125- C207), AIDS, 17(18): F49-54, Dec. 5, 2003 | No | |
| | | TMC 125 as 7d monotherapy in ARV-naïve subjects (TMC 125-C208), AIDS, 17(17): 2487-2494, Nov. 21, 2003 | No | |
| | | TMC 125 similar potency to 5-drug, 3-class regimen, AIDS, 17(18): 2623-2627Dec. 5, 2003 | No | _ |
| | | UDIER-BLAGOVIC, Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125, Journal of American Chemical Society, 2003, 125(20), pp.6016-6017 | No | |
| | • | GULICK, New Antiretroviral drugs, Clinical Microbiology and Infection, 2003, 9(3), pp 186-193 | No . | |
| m | | LUDOVICI, Evolution of anti-HIV drug candidates. Part 3: diarytoyrimidine, (DAPY)anatogues.Bioorganic & Medicinal Chemstry Letters (2001), 11(17), pp. 2235-2239. | No | |
| | | | | 1 |
| | | | | ┼ |
| | | | | 1 |
| | | | | |
| | | | | - |
| | | | ļ | ├ |
| - | | | | + |
| | | | | T |

| | | | | | | <u>.</u> |
|-----------------------|----|-----------|------|--------------------|------|----------|
| Extender Signature | VB | Lalgsuban | -un- | Date Considered | 7129 | 104 |

EXAMPLER; initial if reference considered, whether or not obtain is in conformance with MPEP 805, Draw line through citation if not in conformance and not considered, include copy of this turn with need communication to applicant. Applicant's unique clation designation number (optional). See kinds Codes of USPTO Patent Documents at www.uspto.gov. or MPEP 901.04, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sental number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if postable. ⁶ Applicant is to place a check mark here if English language Translation is attached.

FEB 1 3 ZIM BY FEB 1 ZIM

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

| a conscion of information unless it displays a | Valid Carp Control Humber. |
|--|----------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Named Inventor | Bart De Corte |
| Group Art Unit | 1614 |
| Examiner Name | V. Balasubramanian |
| Attorney Docket Number | JAB 1425 |

| | | | Silect 1 O | | U.S. PATENT DOCUMENTS | | | |
|----------------------|------|---|------------|---|--|--|-----------------|----|
| Examiner Initials | Cite | U.S. Patent Document Kind Code' Number (if known) | | Kind Code ² Name of Pateritee or Applicant of Cited Document | | Date of Publication of Cited Document mm-dd-yyyy | Cited Document | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| <u> </u> | | | | FORE | IGN PATENT DOCUMENTS | | | |
| Examiner Initials | Cite | Foreign Patent Document | | nt ndCode ⁵ | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Translation | T⁵ |
| | NO. | | | | | | | |
| | | | | | - | | | |
| | | | | | | | | |
| M | 1 | EP | 0 588 762 | A1 | CIBA-GEIGY A.G. | 08-23-1993 | To be submitted | |
| | | | | | | | | |
| | | | | | | | | |

Examiner V. Balasuranon Date Considered 7 129104

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible a Applicant is to place a check mark here if English language Translation is attached.

code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00) Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 3

| S consciou or electuratori cances a ceshests . | g falle outs consent territori. |
|--|---------------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Named Inventor | Bart De Corte |
| Group Art Unit | 1614 |
| Examiner Name | V. Balasubramanian |
| Attorney Docket Number | JAB 1425 |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | | |
|----------------|--|--|-------------|----|
| Examiner's | the state of the s | | Translation | ₹2 |
| Initiats* No.' | | GRUZDEV, et al., A Randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve HIV-1 infected subjects, AIDS 2003, VOL 17, pp. 2487- | No | |
| | 3 | SANKATSING, et al., TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen, AIDS 2003, Vol. 17, pp. 2623-2627. | | |
| | 4 | GAZZARD, et al., An open-label assessment of TMC 125 – a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance, AIDS 2003, Vol. 17, pp. 49-54. | | |
| 7 | 5 | LUDOVICI, et al., Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues, Bioorganic & Medical Chemistry Letters 11, 2001, pp. 2235-2239. | | L |
| | 6 | UDIER-BLAGOVIĆ, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnuceloside Inhibitor TMC125, J. AM. CHEM. SOC. 2003, Vol. 125, pp. 6016-6017. | | |
| | 7 | GULICK, New Antiretroviral Drugs, Clinical Microbiology and Infectious Diseases, CMI, 9, (3) pp. 186-193 (March, 2003) | | |
| | 8 | FURUKAWA, et al., Syntheses of Compounds related to Guanidine and their Inhibitory Action on Growth of Hel.a Cells, Chem. Pharm. Bull. 9 (11), 914-921 (1951) | | |
| | 9 | GAZZARD, et al., TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI , CROI, Seattle, Feb. 2002. | | |
| | 10 | VINGERHOETS, et al., Antiviral activity of TMC125, a potent next-generation NNRTI, against > 5000 recombinant clinical isolates exhibiting a wide range of (NNRTI) resistance, XIIth International HIV Drug Resistance Workshop, June 10-14, 2003, Mexico. | | |
| | 11 | VINGERHOETS, et al., Characterization of Resistance Before and After Short-Term Therapy with TMC125 in Patients with Documented NNRTI Resistance, XIIth International HIV Drug Resistance Workshop, June 10-14, 2003, Mexico | | |
| | 12 | GAZZARD, et al., TMC125, a Next Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI- Resistance, XIV International AIDS Conference, July 2002, Barcelona, Spain | | |
| | 13 | SANKATSING, et al., TMC 125 Monotherapy for One Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a 5-Drug Regimen, CROI, Seattle, Feb., 2002. | | |
| My | 14 | ARNOLD, et al., Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21 st European Crystallographic Meeting, Durban, South Africa, 24-29, Aug. 2003. | | ,- |
| | | | | |
| | | | | - |
| | | | | + |

| Examiner | 11/1/2 | Date | 7/28/11 |
|-----------|----------------|------------|---------|
| Signature | V. Dalasuranau | Considered | 112109 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (W/PO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/88A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

| a collection of information unless it displays a | Valid UMB CONDUITUMDET. |
|--|-------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Named Inventor | Bart De Corte |
| Group Art Unit | 1614 |
| Examiner Name | V. Balasubramanian |
| Attorney Docket Number | JAB 1425 |
| | 1 |

| | | OTHER - NON PATENT LITERATURE DOCUMENTS | | |
|------------|--------------|---|-------------|----|
| Examiner's | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), web.mo.issue.number(s), publisher city and/or country where published | Translation | T² |
| M | 15 | DAS, et al., Could multiple modes of binding of a potent NNRTI TMC125-R165335 explain its potency against common drug-resistant mutants? CROI, Boston, Feb. 2003 | | |
| | | | | |
| | | | | |
| | | | | |
| | | · | | |
| | | | | |
| | | | | |

| Examiner | 1. Baler | Subarron | Date Considered | 7/29/04 |
|----------|----------|----------|--------------------|---------|

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usprto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 (hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

FEB 1 7 2004 Substite

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. PATENT DOCUMENTS

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

| a constrain or anounterent grosser are hole | O TODO OTRO DOLLO TRAILOCT. |
|---|-----------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Named Inventor | Bart De Corte |
| Group Art Unit | 1614 |
| Examiner Name | V. Balasubramanian |
| Attorney Docket Number | JAB 1425 |

| | 1 | U.S. Pat | en Document | | Name of Patentee or Applicant | | Date of Publication | an l | Misc. | |
|----------------------|--------------|-------------------------|---|----------------------------------|------------------------------------|--------------------------------------|----------------------------------|-------------|----------------|----|
| Examiner Initials | Cite No.1 | Number | | id Code ² f known) | of Cited Document | | of Cited Document mm-dd-yyyyy | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | FOR | EIGN PATENT DOCUMENTS | | | | | |
| | | Foreign Patent Document | | Name of Patentee or | | ate of Publication Cited Document | | | | |
| Examiner Initials | Cite No.1 | Office ³ | Number ⁴ Ki | ndCode ⁵ | Applicant of Oited Document | | mm-dd-yyyy | | Translation | T⁵ |
| | | | | · | | Γ | | | | |
| | , , , | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | OTHER | R - NON PATENT LITERATURE DOCUM | AENT | ·s | | | |
| | | Include | e name of the | | n CAPITAL LETTERS), title of the a | _ | | te), | | |
| Examiner's Initials* | Cite No.1 | title of | | | | | | Translation | T ² | |
| M | 1 | Encomp Xith Co | Volume-Issue number(s), published. J. VINGERHOETS et al., Antiviral Activity of TMC Against a Panel of Site-Directed Mutants. Encompassing Mutations Observed In Vitro and In Vivo, Poster No. 621, Presented at the XIth Conference on Retrovirus and Opportunistic Infections, Feb 8-11, 2004, San Francisco, CA, USA | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| Examiner C C al C C C C C C C C C C C C C C C C | Date Considered | 7/20/104 | 1 |
|--|--------------------|---|---|
| *EYAMINED: Initial if reference considered whether or not citation is in conformance | | through eligible if not \$4 confermings | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant: a Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if cossible. 4 Applicant is to place a check mark here if English language Translation is attached.

possible. e Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PE JOS TRADECTOR

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Date of Publication

03-27-1985

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

U.S. Patent Document

0135472

| d compensation and annual manage is and and | 2 7000 0100 0010011011011 |
|---|---------------------------|
| Application Number | 09/430,966 |
| Filing Date | 11/01/1999 |
| First Named Inventor | Bart De Corte |
| Group Art Unit | 1614 |
| Examiner Name | V. Balasubramanian |
| Attorney Docket Number | JAB 1425 |
| | |

Misc

English Abstract

| Examiner Initials | Cite No.1 | Number | (if known) | of Cited Document | of Cited Document | | |
|----------------------|--------------------------|-------------------------|---|-----------------------------|--|-------------|----|
| | | | | | | | |
| | <u> </u> | | FORE | GN PATENT DOCUMENTS | | | |
| | | Foreign Pater | nt Document | Name of Patentee or | Date of Publication of Cited Document | | |
| Examiner Initials | Cite No. ¹ | Office ³ Nur | mber ⁴ KindCode ⁵ | Applicant of Cited Document | mm-dd-yyyy | Translation | T⁵ |

CIBA-GEIGY A.G.

U.S. PATENT DOCUMENTS

Name of Patentee or Applicant

| | OTHER - NON PATENT LITERATURE DOCUMENTS | | |
|------------|--|----|--|
| Examiner's | Translation | T² | |
| 100 | volume-issue number(s), publisher, city and/or country where published | No | |
| | | | |
| | | | |

| | | | | | | | | | | _ |
|------------|---------------|------------|--------------------|---------------------|----------------------|-----------------|---------------|-------------------------------|----------------------|---|
| Examiner | \sim | 1 | | | • | | Date | 7/20 | 1 1 ~ 1 | |
| | 1 / 8 | <u>ہ</u> ا | | . | ~ | | | حد ۱۱ | 4 1 CYL - | |
| Signature | 1/ · ¥ | _) /A /L | A(1) | 8 1 2222 | and a | $\overline{}$ | Considered | 1 11 - | 1109 | |
| | | | | | | | | | | |
| SCYALINED. | Initial if as | damaga d | assidamd | whathar or or | d citation is in cor | thu sonemole | MDED 600 Dra | w line through citation if no | t in conformance | |
| | milita ii it | icience (| <i>X</i> 1510E1EU, | , where the current | a cration is in our | HOLLHOLIGE MIDT | MFLF 003. DIS | a mie niiooğii enemeri ii ne | 1 111 00110111191106 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

possible, e Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAR 0 9 2004 BY

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Date of Publication

of Cited Document

mm-dd-yyyy

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. PATENT DOCUMENTS

Name of Patentee or Applicant

of Cited Document

Substitute for form 1449A/PTO

Cite

Examiner

Initials

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

(if known)

U.S. Patent Document

Number

| Application Number | 09/430,966 | | |
|------------------------|--------------------|--|--|
| Filing Date | 11/01/1999 | | |
| First Named Inventor | Bart De Corte | | |
| Group Art Unit | 1624 | | |
| Examiner Name | V. Balasubramanian | | |
| Attorney Docket Number | JAB 1425 | | |

Misc.

| | | | | FOR | EIGN PATENT DOCUMENTS | | | | |
|-------------------------|--------------|--|-----------------------|----------------------|---------------------------------|--|-----|-------------|----|
| | | Foreign Patent Document | | ent | Name of Patentee or | Date of Publication of Cited Document | | | |
| Examiner Initials | Cite No.1 | Office ³ | Number ⁴ K | indCode ⁵ | Applicant of Cited Document | mm-dd-yyyy | | Translation | Τ° |
| W | 1 | EP | 0588762 | A1 | CIBA-GEIGY A.G. | 03-23-1994 | Yes | | |
| | | | | | | | | | I |
| | | | | | | | | | |
| | | | | | | | | | |
| Ŀ | | <u>'——</u> — | | | | | | | |
| | | | | | R - NON PATENT LITERATURE DOCUM | | | | |
| Examiner's Initials* | Cite No.' | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | | T² | | |
| | | | | | | | | | |
| | ļ | | | | | | | | |
| | ļ | | | | | | | | |
| | L | <u> </u> | | | | | | | |

| | | | | _ |
|-----------------------|------------------|--------------------|---------|---|
| Examiner Signature | V. Balasulranoin | Date Considered | 7/29/04 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uscto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible 4 Applicant is to place a check mark here if Fontish language Translation is attached.

possible. a Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.